Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Summary

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.

Timeline

Start

2023-09-27

Primary completion

2025-08-14

Completion

2025-09-09

Outcome

Outcome not reported

Stopped: “Company decision”

Drugs

Indications